Contributed to NME For profit Phase 3
Founded: Burlington MA United States (1989)
Status: Acquired by Shire (2016) → now Takeda (2018)

Organization Overview

First Clinical Trial
2007
NCT00457015
First Marketed Drug
2009
ecallantide (Kalbitor)
First NDA Approval
2018
lanadelumab (shp643) (takhzyro)
Last Known Activity
2018

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Dyax Corp. | DYAX CORP.